咨询-联络案例会议:刺激剂诱导的晚期运动障碍症
Mansoor Malik1, Trung Tran1, Partam Manalai2
1Johns Hopkins University, Baltimore, MD.
Journal of the Academy of Consultation-Liaison Psychiatry
|December 5, 2025
概括
兴奋剂药物可能会导致晚期动力障碍,一种运动障碍,在患有注意力缺陷多动症患者中. 停止使用兴奋剂并切换到诸如他之类的药物可以显著改善症状.
科学领域:
- 精神病学是一个精神病学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 迟性运动障碍 (TD) 是某些药物的严重副作用.
- 兴奋剂药物通常用于注意力缺陷多动障碍 (ADHD).
- 在患有复杂精神病史和多药症的患者中管理TD存在挑战.
研究的目的:
- 在患有注意力缺陷多动症障碍 (ADHD) 和复杂精神疾病的患者中呈现晚期动症 (TD) 病例.
- 突出刺激剂在加剧运动障碍中的作用.
- 审查TD的治疗策略.
主要方法:
- 一个35岁的非二元患者的案例介绍.
- 关于兴奋剂诱导的运动障碍和TD治疗的文献综述.
- 在药物调整后对治疗结果的分析.
主要成果:
- 患者在开始使用安非他林/德克斯托安非他林后发展了TD.
- 停止使用兴奋剂并转换为氨酸导致了TD的显著改善.
- 兴奋剂与,运动障碍和TD有关,特别是在ADHD患者中.
结论:
- 刺激剂诱导的运动障碍,包括TD,需要对ADHD患者进行警监测.
- 对于TD的治疗策略包括停止侵扰性药物,切换抗精神病药物,并考虑使用膀单胺转运体2抑制剂.
- 个性化治疗方法对于高风险患者的TD管理至关重要.
相关概念视频
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Drugs Acting on Autonomic Ganglia: Stimulants
2.0K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K
Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
Therapeutic Drug Monitoring: Overview and Classification
275
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
275


